Actually, ABT is conducting seven all-oral phase-3 HCV trials for genotype-1 patients: the three I cited in #msg-81374289 and four others called SAPHIRE-III, SAPHIRE-IV, TURQUOISE-I, AND PEARL-II.
SAPHIRE-III and SAPHIRE-IV (unlike SAPHIRE-I and –II, where all patients receive ribavirin and the control arm is 12 weeks of full-fledged placebo) test 12 weeks of ABT’s 3-DAA combination +/- ribavirin. SAPHIRE-III is for treatment-naïve genotype-1b and SAPHIRE-IV is for treatment-naïve genotype-1a.
PEARL-II is a clone of SAPHIRE-III except that it is for treatment-experienced genotype-1b patients.
TURQUOISE-I tests HCV/HIV co-infected patients using 12- and 24-week arms of ABT’s 3-DAA cocktail + ribavirin.
All told, these phase-3 trials will have about 2,000 patients. (Source: Today’s AASLD CC.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.